Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study

By Samsioe G.   Boschitsch E.   Concin H.   De Geyter C.   Ehrenborg A.   Heikkinen J.   Hobson R.   Arguinzoniz M.   de Palacios P. Ibarra   Scheurer C.   Schmidt G.   Estalis on behalf of the   Group Study  

Climacteric, Vol. 9, Iss. 5, 2006-10 ,pp. : 368-379

Informa Healthcare

Access to resources Recommend Favorite

Endometrial safety of a transdermal sequential estradiol–levonorgestrel combination

By Sturdee D. W.   van de Weijer P.   von Holst Th.  

Climacteric, Vol. 5, Iss. 2, 2002-06 ,pp. : 170-177

Informa Healthcare

Access to resources Recommend Favorite

The influence of medroxyprogesterone acetate on the effects of transdermal oestradiol replacement therapy on plasma lipids

By Bhathena R. K.   Anklesaria B. S.   Ganatra A. M.   Pinto Rosaline  

Journal of Obstetrics & Gynaecology, Vol. 18, Iss. 2, 1998-03 ,pp. : 141-145

Informa Healthcare

Access to resources Recommend Favorite

Growth effects of raloxifene, estradiol, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells

By Boostanfar R.   Amezcua C.A.   Tourgeman D.E.   Roy S.   Felix J.C.   Stanczyk F.Z.  

Fertility and Sterility, Vol. 79, Iss. 1, 2003-01 ,pp. : 223-225

Elsevier

Access to resources Recommend Favorite

Sequential addition of low dose of medrogestone or medroxyprogesterone acetate to transdermal estradiol: a pilot study on their influence on the endometrium

By Pansini F.   Paoli D.D.   Albertazzi P.   Bonaccorsi G.   Campobasso C.   Zanotti L.   Pisati R.   Giulini N.A.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 68, Iss. 1, 1996-09 ,pp. : 137-141

Elsevier

Access to resources Recommend Favorite